展開選單
About Us
Our Company
Team
Milestone & Recognitions
Partners and Collaborations
Research
Antroquinonol
Pipeline
Clinical trials
Supporting Publications
News & Events
Press Releases
Events
Business Development
Contact Us
搜尋
繁中
EN
收合選單
搜尋
EN
繁體中文
English
HOME
News & Events
Press Releases
Press Releases
May 08, 2023
Golden Biotech Announces Positive Results with Longer Survival Compared with Standard Treatments from Interim Analysis of Phase 2 Trial for Antroquinonol as 1st Line Treatment for Stage 4 Metastatic Pancreatic Cancer
Nov 22, 2022
Golden Biotech Signs the Definitive Licensing Agreement with BNC Korea for the Development of Antroquinonol in COVID-19
Jul 07, 2022
GoldenBiotech Received FDA AoR of its Pre-EUA Meeting Request for COVID-19 Trial Drug Antroquinonol
May 27, 2022
FDA Approves GoldenBiotech's IND Application of Antroquinonol for Phase II Trial on Relapsed Acute Myeloid Leukemia (AML)
Jan 05, 2022
GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Patients
Aug 30, 2021
GoldenBiotech’s Oral COVID-19 New Drug Trial of Antroquinonol Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients
Aug 25, 2021
GoldenBiotech signs MOU with Sanova Pharma GesmbH for cooperation and development of Antroquinonol in 23 European Countries
Jul 02, 2021
GoldenBiotech HOCENA Granted Compassionate Use by the TFDA for Treatment of Covid-19 Patients
Jun 03, 2021
Covid-19 Trial_GoldenBiotech New Drug Antroquinonol Passed 2nd DMC Review in the USA
Apr 19, 2021
GoldenBiotech Completes Second Interim of Patients Enrollment for Covid-19 Phase 2 Clinical Trial_v1
Apr 07, 2021
GoldenBiotech Presents Outstanding Results of Potential Treatment for Relapsed AML in ASCO 2021
Jan 16, 2021
Covid-19 Drug Dual Achievements: GoldenBiotech’s New Drug Antroquinonol (HOCENA) Receives Positive Response from DMC Review and Licenses for 4 Countries
上一頁
1
2
下一頁